T.S.K. Mok
The Chinese University of Hong Kong
Internal medicineOncologyAtezolizumabLung cancerChemotherapyLungChemotherapy regimenDacomitinibnon-small cell lung cancer (NSCLC)CrizotinibPembrolizumabGefitinibAfatinibCarboplatinNon small cellFirst lineIn patientEgfr mutationPhases of clinical researchCancer researchMedicine
129Publications
2H-index
2,438Citations
Publications 9
Newest
Source
#1M.C. Garassino (U of C: University of Chicago)H-Index: 12
#2Delvys Rodriguez-Abreu (ULPGC: University of Las Palmas de Gran Canaria)H-Index: 33
Last. Hande Turna (Istanbul University)H-Index: 14
view all 24 authors...
Background null Pembrolizumab is a standard-of-care first-line treatment for advanced/metastatic NSCLC, either as monotherapy (for patients with PD-L1 tumor proportion score [TPS] ≥1%) or combined with platinum chemotherapy. An improved OS benefit has been demonstrated for both pembrolizumab monotherapy and pembrolizumab plus chemotherapy in patients with higher tumor PD-L1 expression, and for pembrolizumab monotherapy in patients with higher tissue tumor mutation burden (tTMB). Mutations in KRA...
Source
#1Pilar GarridoH-Index: 29
#2Jean-Louis PujolH-Index: 1
Last. T.S.K. Mok (CUHK: The Chinese University of Hong Kong)H-Index: 2
view all 14 authors...
Canakinumab is a human IgGκ monoclonal antibody, with high affinity and specificity for IL-1β. The Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS) trial, evaluating canakinumab for cardiovascular disease, provided the first signal of the potential of IL-1β inhibition on lung cancer incidence reduction. Here, we describe the rationale and design for CANOPY-N, a randomized Phase II trial evaluating IL-1β inhibition with or without immune checkpoint inhibition as neoadjuvant treatme...
Source
#1Martin ReckH-Index: 86
#2Tony Mok (CUHK: The Chinese University of Hong Kong)H-Index: 114
Last. T.S.K. Mok (CUHK: The Chinese University of Hong Kong)H-Index: 2
view all 21 authors...
Summary Background The IMpower150 trial showed significant improvements in progression-free and overall survival with atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) versus the standard-of-care bevacizumab plus carboplatin plus paclitaxel (BCP) in chemotherapy-naive patients with non-squamous non-small-cell lung cancer. Here, we report the efficacy of ABCP or atezolizumab plus carboplatin plus paclitaxel (ACP) versus BCP in key patient subgroups. Methods IMpower150 was a ra...
Source
Source
#1Jean-Charles SoriaH-Index: 98
#2Yi Long WuH-Index: 2
Last. T.S.K. MokH-Index: 2
view all 19 authors...
Summary Background Optimum management strategies for patients with advanced non-small-cell lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase inhibitors are undefi ned. We aimed to assess the effi cacy and safety of continuing gefi tinib combined with chemotherapy versus chemotherapy alone in patients with EGFR-mutation-positive advanced NSCLC with acquired resistance to fi rst-line gefi tinib. Methods The randomised, phase 3, multicentre IMPRESS study was done in 71 centres in...
#1Martin ReckH-Index: 4
#2David F. HeigenerH-Index: 19
Last. Klaus F. RabeH-Index: 108
view all 5 authors...
Non-small-cell lung cancer is one of the leading causes of deaths from cancer worldwide. Therefore, improvements in diagnostics and treatments are urgently needed. In this review, we will discuss the evolution of lung cancer staging towards more non-invasive, endoscopy-based, and image-based methods, and the development of stageadapted treatment. A special focus will be placed on the role of novel surgical approaches and modern radiotherapy strategies for early stages of disease, the eff ect of ...
#1Linda Leung (CUHK: The Chinese University of Hong Kong)H-Index: 5
#2Kwok Chi Lam (CUHK: The Chinese University of Hong Kong)H-Index: 17
Last. T.S.K. Mok (CUHK: The Chinese University of Hong Kong)H-Index: 2
view all 3 authors...
Source
#1Masahiro FukuokaH-Index: 16
Last. T.S.K. MokH-Index: 2
view all 17 authors...
Purpose The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/ paclitaxel in previously untreated never-smokers and light ex-smokers with advanced pulmonary adenocarcinoma were published previously. This report presents overall survival (OS) and efficacy according to epidermal growth factor receptor (EGFR) biomarker status. Patients and Methods In all, 1,217 patients were randomly assigned. Biomarkers analyzed were EGFR mutation (amplification mutation refrac...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.